Tennessee pharmacies dispense concentrated ivermectin without prescriptions in anti-vaccine physician network

Four years after Tennessee legalized prescription-free ivermectin sales, dozens of pharmacies dispense highly concentrated doses under agreements with anti-vaccine physician Denise Sibley.

Objective Facts

Four years ago, Tennessee became the first state to allow adults to buy the antiparasitic drug ivermectin from a pharmacy without first seeing a doctor. The state's law allows pharmacies to dispense ivermectin without a specific prescription for each patient, through a 'collaborative pharmacy practice agreement' with a doctor who provides what is functionally a pre-written, nonspecific prescription for all potential customers. Physician Denise Sibley has signed as many as 40 of these agreements with Tennessee pharmacies, which forward her the paperwork on each ivermectin customer. Highway billboards advertise ivermectin as 'Available Without a Prescription in Tennessee!' while dozens of pharmacies offer highly concentrated pills, sometimes at 10 or 20 times the potency of a standard tablet. Some pharmacy websites claim ivermectin can treat COVID, diabetes, and cancer, though there is no evidence it's effective for those purposes.

Left-Leaning Perspective

Left-leaning outlets, including WPLN News and KFF Health News, framed the June 2026 reporting as exposing the consequences of Republican overreach. KFF Health News reported that the bill was "shepherded by a Republican supermajority in 2022" and "blindsided state medical officials." ABC News conveyed that the law "handed a victory to medical groups that spread COVID-19 misinformation." These outlets emphasized that Denise Sibley, the driving force behind the market, is an anti-vaccine physician who has signed 40 collaborative agreements enabling virtually unrestricted dispensing. WPLN News featured criticism from Timothy Caulfield, who told ABC News the ivermectin market is fundamentally about "profit, political identity, creating distrust in the existing biomedical community," not science. Left-oriented coverage highlighted the dangers: pharmacy websites marketing the drug for COVID, diabetes, and cancer despite no evidence of effectiveness, highly concentrated doses (10-20 times normal strength), and legal immunity shielding pharmacists from accountability. UCLA physician John Mafi was cited expressing concern that ivermectin could lure cancer patients away from proven treatments. The coverage underscored that the law requires pharmacies to ask screening questions but provides "little oversight from health authorities." Left-leaning outlets largely omitted Republican dissent within Tennessee, though some coverage mentioned Sen. Richard Briggs's concerns; they focused heavily on the anti-vaccine framing of Sibley rather than exploring any legitimate therapeutic arguments or the distinction between moderate access and unregulated marketing.

Right-Leaning Perspective

Right-leaning and pro-ivermectin coverage, represented by guest columns and Tennessee Republican statements, emphasized consumer autonomy and safety improvements. Tennessee bill sponsor Sen. Frank Niceley argued in 2022 that pharmacy-guided dosing was safer than people purchasing livestock formulations and guessing at doses—a practical safety argument rather than an endorsement of efficacy claims. Proponents framed the law as protecting the doctor-patient relationship and consumer choice against federal regulatory overreach. Children's Health Defense Tennessee and similar outlets characterized the law as a "victory for consumers, patients, doctors, and pharmacists" and argued ivermectin is "on the World Health Organization's list of top 10 most essential medicines" and "one of the safest drugs ever invented." Pro-access voices emphasized that the law enables patients and doctors to make independent medical decisions. They cited claims of scientific support for ivermectin's effectiveness against COVID and other conditions, framing federal opposition (like the FDA's "horse" tweet) as institutional censorship rather than evidence-based guidance. Right-leaning coverage positioned Sibley's involvement positively, highlighting her commitment to treating patients without payment rather than examining potential conflicts of interest. Right-leaning coverage largely avoided engaging with concerns about highly concentrated doses, the immunity from accountability, or the absence of patient-specific prescriptions; it focused on ideological principles of access and bodily autonomy rather than addressing clinical safety data.

Deep Dive

Tennessee's 2022 ivermectin law emerged from a convergence of COVID-era mistrust of public health institutions, broader skepticism toward federal drug regulation, and the political salience of treatment autonomy. The bill passed with near-unanimous Republican support despite medical board members acknowledging it 'tied their hands' legally and blindsided state health officials. The mechanism—collaborative pharmacy agreements with blanket prescriptions—allowed the law to function as intended by proponents while also enabling unanticipated scale and commercialization, particularly once Denise Sibley signed 40+ agreements with pharmacies seeking to profit from ivermectin demand. Each side's analysis captures real concerns but elides others. The left correctly identifies that a blanket prescription enables sales without individualized physician assessment, that immunity creates perverse incentives for false marketing, and that clinical trials show ivermectin lacks efficacy for COVID. However, left-oriented coverage does not seriously engage with the philosophical or practical argument for greater prescribing flexibility or acknowledge that some practitioners believe ivermectin has therapeutic value based on evidence outside the randomized trial paradigm. The right correctly notes that ivermectin is a safe drug with historical medical use and that federal agencies may have overreached during the pandemic, but does not address how legal immunity from accountability combined with blanket prescriptions creates a market divorced from individual medical need or how 10-20x concentrated doses in someone without a diagnosis differ from standard prescribing. The critical fact is that the gap between the law's stated mechanism (physician collaboration to improve access) and its actual implementation (dozens of pharmacies dispensing highly concentrated ivermectin for undiagnosed conditions under pre-written prescriptions, with immunity from oversight) has widened substantially. Only one Republican legislator, Sen. Richard Briggs, has publicly called for reining in the market, and he acknowledges this will be a 'hard sell' given the political identity ivermectin has acquired. The next legislative moment will be 2027 when Briggs plans to introduce restricting legislation, making this a story to watch for evidence of whether political calculation or clinical concern prevails among Tennessee Republicans.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

Tennessee pharmacies dispense concentrated ivermectin without prescriptions in anti-vaccine physician network

Four years after Tennessee legalized prescription-free ivermectin sales, dozens of pharmacies dispense highly concentrated doses under agreements with anti-vaccine physician Denise Sibley.

Jun 17, 2026
What's Going On

Four years ago, Tennessee became the first state to allow adults to buy the antiparasitic drug ivermectin from a pharmacy without first seeing a doctor. The state's law allows pharmacies to dispense ivermectin without a specific prescription for each patient, through a 'collaborative pharmacy practice agreement' with a doctor who provides what is functionally a pre-written, nonspecific prescription for all potential customers. Physician Denise Sibley has signed as many as 40 of these agreements with Tennessee pharmacies, which forward her the paperwork on each ivermectin customer. Highway billboards advertise ivermectin as 'Available Without a Prescription in Tennessee!' while dozens of pharmacies offer highly concentrated pills, sometimes at 10 or 20 times the potency of a standard tablet. Some pharmacy websites claim ivermectin can treat COVID, diabetes, and cancer, though there is no evidence it's effective for those purposes.

Left says: Left-leaning coverage emphasizes that Republican leadership created a deregulated market dominated by an anti-vaccine physician, enabling false health claims protected by legal immunity while diverting patients from evidence-based treatments.
Right says: Right-leaning and pro-ivermectin coverage frames the law as a consumer protection measure that improves safety while defending patients' rights to access a Nobel Prize-winning medication outside the traditional medical establishment.
✓ Common Ground
Several voices across the political spectrum express concern about whether concentrated ivermectin doses are appropriate for undiagnosed patients without physician oversight—even some Republican legislators like Sen. Richard Briggs worry about the "dangerous" nature of the market and "misleading advertising."
Both left and right acknowledge that ivermectin is a Nobel Prize-winning drug historically used safely for parasitic infections, though they sharply disagree on whether it is effective for COVID and other off-label uses.
Critics on both sides have raised questions about Denise Sibley's role: the left questions whether she is profiting from a market she created; the right has not addressed this potential conflict of interest, though they have celebrated her unpaid treatment of early patients.
Objective Deep Dive

Tennessee's 2022 ivermectin law emerged from a convergence of COVID-era mistrust of public health institutions, broader skepticism toward federal drug regulation, and the political salience of treatment autonomy. The bill passed with near-unanimous Republican support despite medical board members acknowledging it 'tied their hands' legally and blindsided state health officials. The mechanism—collaborative pharmacy agreements with blanket prescriptions—allowed the law to function as intended by proponents while also enabling unanticipated scale and commercialization, particularly once Denise Sibley signed 40+ agreements with pharmacies seeking to profit from ivermectin demand.

Each side's analysis captures real concerns but elides others. The left correctly identifies that a blanket prescription enables sales without individualized physician assessment, that immunity creates perverse incentives for false marketing, and that clinical trials show ivermectin lacks efficacy for COVID. However, left-oriented coverage does not seriously engage with the philosophical or practical argument for greater prescribing flexibility or acknowledge that some practitioners believe ivermectin has therapeutic value based on evidence outside the randomized trial paradigm. The right correctly notes that ivermectin is a safe drug with historical medical use and that federal agencies may have overreached during the pandemic, but does not address how legal immunity from accountability combined with blanket prescriptions creates a market divorced from individual medical need or how 10-20x concentrated doses in someone without a diagnosis differ from standard prescribing.

The critical fact is that the gap between the law's stated mechanism (physician collaboration to improve access) and its actual implementation (dozens of pharmacies dispensing highly concentrated ivermectin for undiagnosed conditions under pre-written prescriptions, with immunity from oversight) has widened substantially. Only one Republican legislator, Sen. Richard Briggs, has publicly called for reining in the market, and he acknowledges this will be a 'hard sell' given the political identity ivermectin has acquired. The next legislative moment will be 2027 when Briggs plans to introduce restricting legislation, making this a story to watch for evidence of whether political calculation or clinical concern prevails among Tennessee Republicans.

◈ Tone Comparison

Left-leaning outlets used urgent, alarmed language—'blindsided,' 'dangerous market,' 'misleading advertising,' 'spread misinformation'—emphasizing institutional failure and patient risk. Right-leaning and pro-access sources used language of liberation and principle—'protecting consumer rights,' 'defending the doctor-patient relationship,' describing the law as a 'victory,' and framing dissent as 'censorship.' The left focused on what could go wrong; the right focused on patient autonomy.